Lab
Genesis Medical Laboratory Corp
Genesis Medical Laboratory Corp was paid $2.59M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 60% of everything it billed.
33Billing provider infoGENESIS MEDICAL LABORATORY CORP
MIAMI, FL 33166
MIAMI, FL 33166
33aNPI1023022019assigned 07/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$2.59M
24GClaims734,995
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#23 of 225
Median peer was paid$74K
This provider vs. median35×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,932 | $22K | |
| 2019 | 118,015 | $35K | |
| 2020 | 136,935 | $380K | |
| 2021 | 134,889 | $1.23M | |
| 2022 | 84,026 | $494K | |
| 2023 | 89,787 | $358K | |
| 2024incomplete | 96,411 | $73K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 60% | 46,280 | 27,108 | $1.55M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 9.6% | 5,493 | 3,280 | $250K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8.1% | 10,776 | 6,988 | $209K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 4.8% | 13,013 | 7,789 | $124K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.5% | 28,802 | 16,520 | $117K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.0% | 36,047 | 25,916 | $53K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 15,797 | 11,493 | $40K |
| 80053 | Comprehensive metabolic panel | 1.3% | 46,135 | 32,768 | $34K |
| 87186 | 1.3% | 12,382 | 8,226 | $33K | |
| 87641 | <1% | 4,381 | 2,933 | $17K | |
| 80061 | Lipid panel | <1% | 40,671 | 29,164 | $16K |
| 84153 | <1% | 5,512 | 4,055 | $15K |
95 more codes
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12,188 | $14K |
| 80074 | <1% | 629 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 53,871 | $13K |
| 82607 | <1% | 19,072 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,816 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32,678 | $7K |
| 86769 | <1% | 1,876 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,519 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,800 | $5K |
| 87088 | <1% | 17,958 | $5K | |
| 80164 | <1% | 2,125 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,673 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 484 | $3K |
| 84480 | <1% | 11,672 | $3K | |
| 82746 | <1% | 15,681 | $3K | |
| 87640 | <1% | 4,375 | $3K | |
| 84436 | <1% | 13,816 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 600 | $2K |
| 84439 | <1% | 5,480 | $2K | |
| 81003 | <1% | 14,103 | $1K | |
| 82570 | <1% | 2,462 | $1K | |
| 82728 | <1% | 7,814 | $1K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 40,148 | $1K |
| 80050 | General health panel | <1% | 193 | $1K |
| 85045 | <1% | 19,591 | $1K | |
| 80076 | <1% | 2,645 | $1K | |
| 83721 | <1% | 4,060 | $980.10 | |
| 81001 | <1% | 15,296 | $946.06 | |
| 86696 | <1% | 184 | $915.57 | |
| 84466 | <1% | 7,779 | $862.62 | |
| 84479 | <1% | 9,739 | $813.96 | |
| 86703 | <1% | 322 | $764.18 | |
| 87581 | <1% | 522 | $633.24 | |
| 86695 | <1% | 182 | $598.48 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 484 | $549.00 |
| 86480 | <1% | 36 | $480.36 | |
| 82533 | <1% | 381 | $473.53 | |
| 83970 | <1% | 459 | $458.73 | |
| 84481 | <1% | 416 | $454.17 | |
| 83540 | <1% | 11,510 | $438.20 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 633 | $428.54 |
| 82140 | <1% | 309 | $408.17 | |
| 85610 | <1% | 4,244 | $362.49 | |
| 84100 | <1% | 5,526 | $356.62 | |
| 83735 | <1% | 4,981 | $331.28 | |
| 86592 | <1% | 458 | $314.32 | |
| 87500 | <1% | 3,471 | $287.10 | |
| 84550 | <1% | 7,889 | $277.66 | |
| 87184 | <1% | 736 | $268.80 | |
| 82378 | <1% | 627 | $239.62 | |
| 84403 | <1% | 436 | $213.01 | |
| 83090 | <1% | 1,400 | $198.51 | |
| 85730 | <1% | 1,230 | $152.69 | |
| 82670 | <1% | 265 | $144.23 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $140.40 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56 | $139.40 |
| 86038 | <1% | 746 | $134.12 | |
| 86140 | <1% | 2,276 | $128.96 | |
| 82044 | <1% | 4,691 | $106.99 | |
| 80305 | <1% | 24 | $82.27 | |
| 85651 | <1% | 2,577 | $78.55 | |
| 83550 | <1% | 471 | $71.34 | |
| 82270 | <1% | 806 | $69.97 | |
| 84144 | <1% | 253 | $66.77 | |
| 84154 | <1% | 439 | $64.74 | |
| 80069 | <1% | 115 | $55.87 | |
| 83525 | <1% | 487 | $32.58 | |
| 82784 | <1% | 458 | $28.16 | |
| 87070 | <1% | 94 | $26.10 | |
| 82550 | <1% | 1,303 | $14.19 | |
| 85044 | <1% | 542 | $12.96 | |
| 86430 | <1% | 321 | $12.29 | |
| 82465 | <1% | 14 | $11.68 | |
| 86225 | <1% | 321 | $11.34 | |
| 87077 | <1% | 16 | $10.94 | |
| 86161 | <1% | 305 | $9.72 | |
| 86160 | <1% | 327 | $9.72 | |
| 86431 | <1% | 386 | $8.02 | |
| 86063 | <1% | 152 | $7.30 | |
| 86060 | <1% | 106 | $4.87 | |
| 82043 | <1% | 110 | $1.64 | |
| 86200 | 0% | 97 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 8,313 | $0.00 |
| 86235 | 0% | 113 | $0.00 | |
| 82274 | 0% | 124 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 47 | $0.00 |
| 86694 | 0% | 43 | $0.00 | |
| 87634 | 0% | 482 | $0.00 | |
| 82272 | 0% | 18 | $0.00 | |
| 82565 | 0% | 41 | $0.00 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 54 | $0.00 |
| 82150 | 0% | 23 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 18 | $0.00 |
| 83690 | 0% | 25 | $0.00 | |
| 86803 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTINEZ, HERIBERTO (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Complete Bio Solutions INC | Miami, FL | $6.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.